Immunotherapy of lung cancer with Corynebacterium parvum |
| |
Authors: | Houshang Moayeri Hiroshi Takita J E Sokal |
| |
Institution: | (1) Department of Medicine B, Roswell Park Memorial Institute, New York State Department of Health, 666 Elm Street, 14263 Buffalo, New York, USA;(2) Department of Thoracic Surgery, Roswell Park Memorial Institute, New York State Department of Health, 666 Elm Street, 14263 Buffalo, New York, USA |
| |
Abstract: | Summary Thirty-one patients with inoperable carcinoma of the lung, excluding oat-cell carcinoma, were randomized to receive either chemotherapy alone, with methyl CCNU and vinblastine every 6–8 weeks (15 Pts) or such chemotherapy plus immunotherapy with IV infusions of Corynebacterium parvum (16 Pts). Prior duration of the disease was longer, and more patients had received previous therapy, in the immunotherapy group; these groups were otherwise very similar. In vitro lymphocyte response to phytohemagglutinin did not change significantly in either group, but the weaker response to Varidase declined in both groups after chemotherapy. An increased baseline level of circulating B lymphocytes was sharply reduced in the C. parvum group. There were no differences in -globulins or delayed skin test responses between immunotherapy and control patients at entry into this study or on follow-up. Median survival from entry was longer in the immunotherapy group (6 months) than in the control group (3 months), but this difference was not statistically significant and only two patients in each group lived for more than 11 months. It is conceivable that more benefit from C. parvum might have been recorded had more effective chemotherapy been available. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|